12.3.2009 - Reata Announces Recent Conferences Participation

IRVING, TX -- December 3, 2009 -- Reata Pharmaceuticals, Inc. announces the company's recent participation at the following investor conferences.

8^th Annual BIO Investor Forum

San Francisco, CA

Presentation by Jason Wilson, Vice President of Finance

Thursday, October 29, 2009

12:30 p.m., PST

Oppenheimer 20^th Annual Healthcare Conference

New York, NY

Presentation by Warren Huff, President and Chief Executive Officer

Tuesday, November 3, 2009

1:15 p.m., EST

Lazard Capital Markets 6^th Annual Healthcare Conference

New York, NY

Presentation by Jason Wilson, Vice President of Finance

Wednesday, November 18, 2009

2:45 p.m., EST

Piper Jaffray 21^st Annual Health Care Conference

New York, NY

Presentation by Warren Huff, President and Chief Executive Officer

Wednesday, December 2, 2009

12:10 p.m., EST

The speakers highlighted clinical data from the company's lead program, bordoxolone methyl, a first-in-class Antioxidant Inflammation Modulator (AIM) in late-stage development for chronic kidney disease.  Reata's clinical development plan for bardoxolone methyl, including an update on the ongoing Phase 2b/3 trial in Stage 3b and 4 chronic kidney disease patients, was also presented, along with upcoming milestones and opportunities. 

About Chronic Kidney Disease

 CKD is a progressive loss of kidney function over a period of months or years, which can be caused by a number of conditions, including diabetes and high blood pressure.  As kidney disease gets worse, waste products can build to high levels in the blood and patients may develop complications like high blood pressure, anemia (low blood count), weak bones, poor nutritional health and nerve damage.  CKD also increases the risk of having heart and blood vessel disease.  As kidney disease progresses, it eventually leads to kidney failure, requiring dialysis or a kidney transplant.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. Reata is the leader in discovering and developing novel anti-inflammatory drugs targeting Nrf2, which controls the body's production of antioxidant and detoxification enzymes and has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress.  Reata is developing a portfolio of AIMs for a variety of inflammation-related diseases.  The company's most advanced program is in late-stage clinical development for the treatment of CKD, a progressive condition affecting more than 26 million Americans.  For more information, visit www.reatapharma.com.

Download PDF